Journal article
Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: Towards a national HPV surveillance strategy
JML Brotherton, JM Kaldor, SM Garland
Sexual Health | Published : 2010
DOI: 10.1071/SH09137
Abstract
This paper describes a possible multifaceted approach to human papillomavirus (HPV) related surveillance in Australia following implementation of a national HPV vaccination program. We describe eight main components: monitoring of vaccine coverage, vaccine safety, type-specific HPV infection surveillance, cervical cytology (Pap screening) coverage and screen detected lesion prevalence, cervical cancer incidence and mortality, genital wart incidence, incidence of recurrent respiratory papillomatosis, and knowledge, attitudes and beliefs about HPV and HPV vaccination. Australia is well placed to monitor the impact of its HPV vaccination program as well as to measure vaccine effectiveness with ..
View full abstractGrants
Funding Acknowledgements
[ "JMLB was an investigator on an investigator-driven study of HPV prevalence in Australia that received partial equal and unrestricted grant funding from CSL Ltd and GlaxoSmithKline (GSK). She was also an investigator on a serosurvey of HPV antibodies in Australia that received funding for the laboratory testing component from CSL Ltd.", "JMK is a co-investigator on a research project that has received support from Merck and CSL Ltd through the provision of the HPV vaccine (Gardasil).", "SMG has received advisory board fees and grant support from CSL and GSK, and lecture fees from Merck and GSK. She has received funding through her institution to conduct HPV vaccine studies for MSD and GSK. SMG is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV prophylactic vaccines." ]